XHKG1066
Market cap2.66bUSD
Dec 23, Last price
4.57HKD
1D
1.11%
1Q
-4.19%
Jan 2017
-11.78%
Name
Shandong Weigao Group Medical Polymer Co
Chart & Performance
Profile
Shandong Weigao Group Medical Polymer Company Limited engages in the research and development, production, and sale of single-use medical devices in the People's Republic of China. It operates through Medical Device Products, Orthopaedic Products, Interventional Products, Pharma Packaging Products, Blood Management Products, and Others segments. The company offers vascular and non-vascular access infusion devices, infusion sets, syringes, puncture needles, and specialized single-use clinical collection kits; wound sutures, wound healing dressings, and wound cleaning and nonvascular catheter supporting extracorporeal devices; and blood collection, storage, separation, and sterilization equipment. It also provides prefilled syringes and pre-filled flush syringes; blood collection and blood glucose testing devices; and general anesthesia consumables, local anesthesia consumables, anesthesia auxiliary consumables, ICU equipment, and open and minimally invasive surgical equipment. In addition, the company engages in the production and sale of orthopedic devices; tumor and blood vessel interventional instruments; implantation materials and artificial organs; medical PVC granules, plastic packing bags, and carton boxes; industrial automatic equipment and parts; molds; hemodialysis equipment; and type I, type II, and type III medical devices. Further, it is involved in the finance leasing and factoring business; wholesale of type I medical devices, surgical devices, and other disposal medical products; provision of asset management, enterprise consulting, enterprise management advisory services, as well as logistics and storage services, as well as export its products. The company offers its products under the Jierui, Wego Ortho, Yahua, Bangde, and Hai Xing brands. It serves hospitals, blood stations, and other medical units; and distributors. The company was incorporated in 2000 and is based in Weihai, the People's Republic of China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 13,229,453 -2.86% | 13,619,007 3.55% | 13,151,719 15.92% | |||||||
Cost of revenue | 11,011,490 | 10,596,243 | 10,147,920 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 2,217,963 | 3,022,764 | 3,003,799 | |||||||
NOPBT Margin | 16.77% | 22.20% | 22.84% | |||||||
Operating Taxes | 307,585 | 424,267 | 415,093 | |||||||
Tax Rate | 13.87% | 14.04% | 13.82% | |||||||
NOPAT | 1,910,378 | 2,598,497 | 2,588,706 | |||||||
Net income | 2,001,906 -27.57% | 2,764,093 21.45% | 2,275,929 9.06% | |||||||
Dividends | (732,633) | (741,638) | (653,288) | |||||||
Dividend yield | 2.13% | 1.28% | 1.49% | |||||||
Proceeds from repurchase of equity | (36,530) | (70,496) | 554,564 | |||||||
BB yield | 0.11% | 0.12% | -1.26% | |||||||
Debt | ||||||||||
Debt current | 2,573,337 | 990,131 | 624,316 | |||||||
Long-term debt | 1,723,248 | 3,634,666 | 3,593,939 | |||||||
Deferred revenue | 76,736 | 88,070 | ||||||||
Other long-term liabilities | 499,505 | 37,001 | 522,849 | |||||||
Net debt | (4,934,337) | (4,091,119) | (3,831,273) | |||||||
Cash flow | ||||||||||
Cash from operating activities | 2,798,529 | 2,214,574 | 3,035,163 | |||||||
CAPEX | (647,577) | (1,116,239) | (1,116,882) | |||||||
Cash from investing activities | (1,388,592) | (2,568,963) | (1,479,374) | |||||||
Cash from financing activities | (2,157,858) | (1,020,957) | (538,080) | |||||||
FCF | 1,472,797 | 761,162 | 1,373,938 | |||||||
Balance | ||||||||||
Cash | 7,333,313 | 7,357,615 | 7,058,679 | |||||||
Long term investments | 1,897,609 | 1,358,301 | 990,849 | |||||||
Excess cash | 8,569,449 | 8,034,966 | 7,391,942 | |||||||
Stockholders' equity | 20,628,179 | 20,529,200 | 18,303,861 | |||||||
Invested Capital | 20,092,078 | 19,644,776 | 17,998,019 | |||||||
ROIC | 9.62% | 13.81% | 15.08% | |||||||
ROCE | 7.74% | 10.84% | 11.73% | |||||||
EV | ||||||||||
Common stock shares outstanding | 4,518,901 | 4,526,649 | 4,516,323 | |||||||
Price | 7.61 -40.64% | 12.82 31.76% | 9.73 -42.97% | |||||||
Market cap | 34,388,837 -40.74% | 58,031,640 32.06% | 43,943,823 -42.67% | |||||||
EV | 30,998,084 | 55,718,187 | 41,752,909 | |||||||
EBITDA | 3,129,667 | 3,825,276 | 3,727,612 | |||||||
EV/EBITDA | 9.90 | 14.57 | 11.20 | |||||||
Interest | 272,971 | 191,401 | 140,396 | |||||||
Interest/NOPBT | 12.31% | 6.33% | 4.67% |